INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10786760				
Filing Date		2004-02-25				
First Named Inventor Daryl		B. Olander				
Art Unit		3621				
Examiner Name						
Attorney Docket Numb	er	BEAS-01405US1				

				U.S.	PATENTS	Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear	
	1	6874143		2005-03-29	Murray et al.		
	2	7069507		2006-06-27	Alcazar et al.		
	3	6601113		2003-07-29	Koistinen et al.		
	4	6516322		2003-02-04	Moredith		
	5	6754884		2004-06-22	Lucas et al.		
	6	6971096		2005-11-29	Ankireddipally et al.		
	7	7043722		2006-05-09	Bau II		
	8	7184967		2007-02-27	Mital et al.		

Application Number 10786760

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Filing Date			2004-02-23					
			First Named	First Named Inventor Dary		f B. Olander					
			Art Unit	Art Unit		3621					
			Examiner Na	Examiner Name							
				Attorney Doc	ket Numb	er	BEAS-01405US1				
	9	7240331		2007-07-03 Vion-Dury et al.							
f you wis	h to ac	dd additional U.S. Paten	t citatio	n information pl	ease click	the A	dd button.		Add		
			U.S.P	ATENT APPLIC	CATION P	UBLIC	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20040078373		2004-04-22	Ghoneimy et al.						
	2	20020194244		2002-12-19	Raventos						
	3	20020111922		2002-08-15	Young et a	al.					
	4	20040040011		2004-02-26	Bosworth et al.						
f you wis	h to ac	dd additional U.S. Publis	hed Ap	plication citation	n informati	on ple	ase click the Add	button.	Add		

FOREIGN PATENT DOCUMENTS Remove Pages,Columns,Lines Name of Patentee or Examiner Cite Foreign Document Country Kind Publication where Relevant Applicant of cited Initial* No Number3 Code2 i Codes Date Passages or Relevant Document Figures Appear

If you wish to add additional Foreign Patent Document citation information please click the Add button Add Remove NON-PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), T٥ Initials* No publisher, city and/or country where published.

	Application Number		10786760	
	Filing Date		2004-02-25	
INFORMATION DISCLOSURE	First Named Inventor	tor Daryl B. Olander		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3621	
(NOCIOI SUDMISSION UNION 37 OF K 1.33)	Examiner Name			
	Attorney Docket Numb	er	BEAS-01405US1	

1	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Petent Documents at Invest_USETO_GOL/or MPEP 901.04. 2 Enter office that issued the document, by the Involved row (MPD Standard ST.3). 3 "For Lapraence patient for counters, the orbidation of the parent of the register or many precess the serial runber of the patient document.

Vinci of Counters by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here if English languages translation is altitude.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10786760
Filing Date		2004-02-25
First Named Inventor	Daryl	B. Olander
Art Unit		3621
Examiner Name		
Attorney Docket Number		BEAS-01405US1

CERTIFICATION STATEMENT

Diagra can	37	CFR 1	97	and 1	QR to	make the	appropriate	colortion/c	· Ar

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) in

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

To the agricult.							
	Signature	/Joseph P. O'Malley/	Date (YYYY-MM-DD)	2007-08-03			
	Name/Print	Joseph P. O'Malley	Registration Number	36226			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.